Semaglutide and NT-proBNP in obesity-related HFpEF: insights from the STEP-HFpEF program
Both medications treat obesity and many related metabolic conditions, Isaacs said
Semaglutide activates GLP-1 receptors in the stomach and intestines and slows gastric motility, which the article says may delay absorption of oral medications, including antibiotics, by 30 to 60 minutes or more
People dealing with both conditions where the obesity is likely contributing to mental health symptoms (through inflammation, metabolic effects, weight stigma) and the mental health symptoms are contributing to obesity (through effects on eating, activity, sleep, stress hormones)
Differences between GLP-1R agonists GLP-1R agonists already in the market and others in development present the same mode of action and, having the same pleiotropic effects of native GLP-1, the differences in clinical profiles between them are related to differences in pharmacokinetics, structure and size of each formulation
